Newsroom
Sorted by: Latest
-
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV at the European Association for the Study of the Liver (EASL) Annual Congress 2026. The late-breaking data, titled ‘First evidence of elimination...
-
バイオサイトジェン、AI駆動型「RenSuper™」プラットフォームと業界初となる完全自動の抗体創薬インフラを発表
中国・北京--(BUSINESS WIRE)--(ビジネスワイヤ) -- バイオサイトジェンは、実験的に検証済みの完全ヒト治療用抗体配列から成る大規模な既製ライブラリーを利用できる次世代のAI駆動型抗体創薬プラットフォーム「RenSuper Workstation」と、抗体検証・製造の加速を目的に設計された完全自動インフラ「RenSuper High-Throughput Antibody Manufacturing Automation Center」を発表しました。 バイオサイトジェン独自のRenMice® プラットフォーム群を基盤として、RenSuperは、生体内免疫レパートリー、AIによる候補選定、自動化された実験検証、拡張可能な製造インフラを組み合わせたクローズド・ループ型抗体創薬エンジンを構築します。同プラットフォームにより、モノクローナル抗体、二重特異性抗体、多重特異性抗体、抗体薬物複合体(ADC)、VHH抗体、その他の高度な治療モダリティーの創薬・開発が支援され、抗体創薬に伴う所要時間とリスクを大幅に削減できます。 RenSuper Workstation:AI駆動型...
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Commonwealth Bank of Australia Issue of AUD 13,000,000.00 Floating Rate Notes due 24 February 2032 Series no 6455 Tranche 1 MTN ISSUE NAME. Our Ref. MO4624 ISIN Code. XS2448367800 TOTAL INTEREST AMT. CURRENCY CODE. AUD DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 90 INTEREST RATE. 5.3459 PCT VALUE DATE. 24/08/2026 INTEREST PERIOD. 26/05/2026 TO 24/08/2026 AUD 171,361.73 POOL FACTOR. N/A...
-
Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares
LONDON--(BUSINESS WIRE)-- Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 26 May 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 26 May 2026 Number of Public Shares Purchased: 21,830 Sha...
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- ASB BANK LIMITED Issue of USD 18,000,000.00 Senior Notes due March 2028 Series 6513 Tranche 1 MTN ISSUE NAME. Our Ref. MP4215 ISIN Code. XS2592796747 TOTAL INTEREST AMT. CURRENCY CODE. USD DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 4.74533 PCT VALUE DATE. 02/06/2026 INTEREST PERIOD. 02/03/2026 TO 02/06/2026 USD 218,285.18 POOL FACTOR. N/A...
-
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (between 1.0 and 1.67×ULN) experienced reductions in ALP after treatment. These data highlight the potential role of Livdelz...
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Australia and New Zealand Banking Group Issue of USD 65,000,000.00 Floating Rate Notes due 2 March 2028 Series 2090 Tranche 1 MTN ISSUE NAME. Our Ref. MP4290 ISIN Code. XS2593135036 INTEREST AMT PER DENOM. CURRENCY CODE. USD DAY BASIS. Actual/360 (A004) NUM OF DAYS. 92 INTEREST RATE. 4.44533 PCT VALUE DATE. 02/06/2026 INTEREST PERIOD. 02/03/2026 TO 02/06/2026 USD 200,000.00 IS USD 2,272.06 POOL FACTOR. N/A...
-
TotalEnergies: Disclosure of Transactions in Own Shares
PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from May 18 to May 22, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/shar...
-
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses
LONDON--(BUSINESS WIRE)--Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expandin...
-
TotalEnergies SE UK Regulatory Announcement: Transactions in Own Shares
PARIS--(BUSINESS WIRE)-- In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from May 18 to May 22, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Amount of tr...